GLP-1 has become one of the most recognizable names in weight-management research, largely because of medications such as semaglutide. But GLP-1 is only one of the hormonal signals involved in appetite, digestion and blood sugar regulation. Another hormone, called amylin, is attracting attention as researchers investigate new approaches to obesity treatment.
Amylin and GLP-1 can produce some similar effects, including helping people feel full and reducing food intake, but they act through different receptor systems. That distinction has led to the development of amylin-based compounds such as cagrilintide and eloralintide, as well as treatments designed to engage both pathways. Researchers are also investigating whether amylin-based approaches might influence body composition—how much of the weight lost comes from fat versus lean tissue.
What Is Amylin?
Amylin is a peptide hormone produced by the pancreas and released alongside insulin, particularly in response to eating. While insulin helps the body manage circulating glucose, amylin contributes to the regulation of food intake and the rise in blood sugar that follows a meal.
One of amylin’s important roles is promoting satiation—the process that helps bring a meal to an end. It acts on receptors involved in communication between the body and brain, including pathways in the brainstem that respond to signals about food intake. Amylin also slows gastric emptying and helps suppress glucagon release after meals, contributing to post-meal glucose regulation.
Natural amylin is not especially convenient as a long-acting medication because it is cleared relatively quickly and presents formulation challenges. Researchers have therefore developed amylin analogues: compounds designed to reproduce selected effects of the hormone while remaining active for longer or interacting with its receptors in more targeted ways.
What Is GLP-1?
GLP-1, or glucagon-like peptide-1, is an incretin hormone released from the intestine in response to food. It helps regulate blood sugar by stimulating insulin secretion when glucose levels are elevated and reducing glucagon secretion. It also influences appetite and gastric emptying through signaling involving the digestive system and brain.
Medications such as semaglutide are GLP-1 receptor agonists. Rather than supplying the natural hormone itself, they activate the GLP-1 receptor in a way that produces longer-lasting effects. GLP-1 receptor agonists are established treatments for type 2 diabetes and, for certain medications and indications, chronic weight management.
Although both amylin and GLP-1 are involved in the body’s response to eating, they are not the same hormone. Amylin is released from pancreatic beta cells alongside insulin, while GLP-1 is primarily released from intestinal cells. They also act through different receptor systems, which is central to understanding why researchers are interested in combining their effects.
Amylin vs GLP-1: The Main Differences
| Feature | Amylin | GLP-1 |
|---|---|---|
| Main source in the body | Pancreatic beta cells | Primarily intestinal L cells |
| Receptor pathway | Amylin receptors | GLP-1 receptors |
| Role in eating | Helps promote meal-ending satiation | Influences appetite, fullness and food intake |
| Blood sugar effects | Helps regulate post-meal glucagon release and gastric emptying | Stimulates glucose-dependent insulin secretion and reduces glucagon release |
| Examples of related compounds | Pramlintide, cagrilintide, eloralintide | Semaglutide, liraglutide |
The overlap in their effects can make amylin and GLP-1 sound interchangeable, particularly when both are discussed in connection with appetite and body weight. Their differences become clearer when looking at how each pathway influences eating behaviour and glucose regulation.
GLP-1 receptor activation has a well-established role in stimulating insulin secretion in a glucose-dependent manner. Amylin’s actions are more closely associated with meal-ending satiation, post-meal glucagon regulation and signaling through amylin-sensitive neural pathways. These descriptions are not exclusive: both hormones have several effects, and their actions can intersect.
The research question is whether engaging these pathways separately or together can produce different effects on appetite, body weight, body composition and tolerability.
Why Are Researchers Studying Amylin-Based Peptides for Weight Management?
GLP-1 medications have demonstrated that targeting appetite-related hormonal pathways can produce substantial changes in body weight. However, appetite regulation involves multiple signals, and people do not respond identically to every treatment. Researchers are studying amylin-based compounds to investigate another pathway that may be used independently or alongside GLP-1 receptor activation.
Earlier amylin research led to pramlintide, an amylin analogue used in diabetes treatment. More recent development has focused on compounds engineered for longer-lasting activity, including cagrilintide and eloralintide. These newer compounds differ in their receptor activity and other pharmacological properties, so they should not be treated as interchangeable simply because they are described as amylin-based peptides.
Clinical trials of newer amylin-based treatments have reported reductions in body weight, but the results depend on the specific compound, study population, treatment duration and trial design. Gastrointestinal adverse effects, including nausea and vomiting, remain important considerations. Evidence from one compound or trial cannot automatically be applied to every amylin analogue.
Could Amylin-Based Peptides Help Preserve Muscle During Weight Loss?
One of the concerns surrounding substantial weight loss is that people can lose lean tissue along with body fat. This is particularly relevant to anyone trying to improve body composition rather than simply reduce the number on the scale. Researchers are therefore interested in treatments that might produce a greater proportion of fat loss while limiting the loss of lean tissue.
Studies of GLP-1-based weight-loss treatments have documented reductions in both fat mass and lean mass. A systematic review of body-composition studies found that the amount of lean or muscle-related tissue lost varied considerably across treatments and studies. This does not mean that GLP-1 medications uniquely cause muscle wasting: lean-tissue loss can also accompany weight loss achieved through other methods.
Amylin has attracted interest partly because animal research suggests that some amylin-based treatments may produce weight loss with relative preservation of lean mass. In one study involving rats with diet-induced obesity, eloralintide produced fat-mass reductions comparable to cagrilintide while causing less lean-mass loss. That finding suggests that body-composition effects may differ even between compounds targeting the amylin pathway.
However, the rat study compared eloralintide with cagrilintide—not with semaglutide or another GLP-1 medication. It therefore cannot establish that eloralintide preserves more muscle than GLP-1 treatments in people.
Human findings also require a more cautious interpretation. A body-composition substudy of a 48-week eloralintide trial reported that approximately 60–70% of the weight reduction in the studied groups came from fat loss. Lean mass also declined, and the reported proportion of fat loss was described as comparable to that seen with other obesity treatments. These results do not demonstrate that eloralintide prevents lean-tissue loss or provides a muscle-preservation advantage over GLP-1 medications.
Likewise, a clinical trial of the cagrilintide–semaglutide combination reported reductions in both fat mass and lean soft-tissue mass. Adding an amylin-based compound to a GLP-1 medication therefore should not be assumed to eliminate lean-tissue loss during weight reduction.
There is also an important distinction between lean mass and skeletal muscle. Body-composition measurements of lean mass include water, organs and other non-fat tissues in addition to muscle. A treatment that produces less measured lean-mass loss has not necessarily been shown to protect muscle size, strength or physical function.
The possibility of preserving more lean tissue is a legitimate reason to study amylin-based treatments, but it remains an area of investigation rather than an established advantage over GLP-1 medications. Direct human comparisons using reliable body-composition measurements—and ideally measures of muscle strength and function—are needed to answer that question.
Where Do Cagrilintide and Eloralintide Fit In?
Cagrilintide and eloralintide are two examples of investigational, long-acting amylin-based compounds. They share an interest in the amylin pathway, but their receptor profiles are not identical.
Cagrilintide
Cagrilintide is a long-acting amylin analogue that has been studied on its own and in combination with semaglutide. Its activity includes amylin and calcitonin receptor signaling, making its receptor profile different from that of a more selective amylin receptor agonist.
The cagrilintide–semaglutide combination, known as CagriSema, is being investigated to determine what happens when amylin-related and GLP-1-related pathways are engaged together. It is a combination of two compounds, not a single peptide that activates both receptors. Clinical trials have examined its effects on body weight, blood sugar and tolerability.
Eloralintide
Eloralintide, also known as LY3841136, is an investigational long-acting compound designed to selectively activate amylin receptors. Its development illustrates a different approach within the amylin field: studying whether more selective receptor activity can influence appetite and body weight while producing a distinct tolerability profile.
Eloralintide is not a GLP-1 receptor agonist. Although its research goals overlap with those of GLP-1 medications, it targets a different hormonal pathway. Its early body-composition findings have also contributed to interest in how different amylin-based compounds may affect the balance between fat loss and lean-tissue loss.
Why Combine Amylin and GLP-1 Pathways?
Combining amylin and GLP-1 activity is being studied because the two pathways can influence overlapping outcomes through different mechanisms. Rather than relying on one receptor system alone, a combination treatment may engage several processes involved in appetite regulation and food intake.
CagriSema is one example of this strategy. Another approach is to design a single molecule capable of activating both amylin and GLP-1 receptors, rather than administering two separate compounds. These are different drug-development strategies, even though both aim to engage the two pathways.
Combining pathways does not automatically mean a treatment will be more effective, better tolerated or more protective of lean tissue for every person. Trial outcomes must be assessed using actual results, including adverse effects, treatment discontinuation and body-composition measurements, rather than assuming that adding another hormonal target will always improve the outcome.
Are Amylin-Based Peptides the Same as GLP-1 Medications?
No. Amylin-based compounds and GLP-1 receptor agonists are related by their roles in metabolic and appetite research, but they do not belong to the same receptor-targeting class.
This distinction is especially useful when comparing newer compounds. Semaglutide acts on the GLP-1 receptor. Eloralintide targets amylin receptors. Cagrilintide has an amylin-related receptor profile that also includes calcitonin receptor activity. CagriSema combines cagrilintide and semaglutide to engage both pathways.
These differences help explain the growing variety of peptide-based approaches being investigated for weight management. They do not, on their own, establish which treatment is appropriate for an individual or whether one investigational compound will preserve more muscle than another.
What Does the Research Still Need to Establish?
The growing interest in amylin-based treatments is supported by clinical research, but important questions remain. Longer-term studies are needed to understand the durability of weight changes, safety and tolerability across different populations, and how individual compounds compare under similar trial conditions.
Body composition is another important research priority. Studies need to establish whether particular amylin-based treatments can consistently reduce fat while limiting lean-tissue loss, whether any such effect differs from GLP-1-based treatments, and whether changes in measured lean mass translate into meaningful differences in muscle strength or physical function.
Researchers are also investigating whether differences in receptor selectivity affect the balance between appetite-related effects and gastrointestinal symptoms. An amylin analogue that selectively activates certain receptors may not produce the same effects as one with broader amylin and calcitonin receptor activity, but those differences need to be demonstrated clinically rather than inferred from receptor profiles alone.
It is also important to distinguish results obtained with a specific pharmaceutical formulation in a clinical trial from claims made about an unapproved research product. A compound’s name or stated purity does not establish that a product has the same formulation, quality, safety or clinical evidence as the material used in published studies.
Final Thoughts
Amylin and GLP-1 are different peptide hormones that help regulate the body’s response to food. Both can influence appetite and food intake, but they originate from different tissues and act through different receptor pathways.
The development of cagrilintide, eloralintide and treatments that engage both amylin and GLP-1 signaling reflects an expanding area of metabolic research. The possibility that some amylin-based compounds could influence the balance between fat loss and lean-tissue loss is particularly interesting, but a muscle-preservation advantage over GLP-1 medications has not yet been established in humans.
Understanding these distinctions makes it easier to follow the research without assuming that every new weight-management peptide works like semaglutide—or that compounds targeting the same general outcome are interchangeable.
Disclaimer
This article is for educational and informational purposes only and does not provide medical advice, treatment recommendations or instructions for using peptides. References to investigational compounds and clinical trials do not establish that a product is approved, safe or appropriate for personal use. Medication approval, availability and permitted uses vary by jurisdiction. Consult a qualified healthcare professional about medical conditions and treatment decisions.